An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors

Purpose: Anaplastic lymphoma kinase (ALK) dysregulation is implicated in numerous cancers. Tyrosine kinase inhibitors (TKIs) targeting ALK have improved disease outcomes, but resistance mechanisms are common. This first-in-human trial evaluates ESK-440, a dual inhibitor of ALK and focal adhesion kin...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Russell J. Schilder, Drew Rasco, Manish R. Sharma
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-03-01
coleção:	Neoplasia: An International Journal for Oncology Research
Assuntos:	Anaplastic lymphoma kinase (ALK) Focal adhesion kinase (FAK) Solid tumors ESK-440 Tyrosine kinase inhibitor (TKI)
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1476558625000120
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!